NCT01540994

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

Phase I/II Trial of Stereotactic Hypofractionated Radiotherapy of the Prostate

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Sharp HealthCare · Academic / Other
• Sex: Male
• Age: 50 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate a short course (five radiation treatments) of very focused ("stereotactic") external beam radiation therapy for the treatment of early stage prostate cancer.

Detailed description

External beam radiation therapy for prostate cancer, while effective, takes up to 9 weeks to deliver on a Monday through Friday basis. Recent phase I/II studies from Seattle and Palo Alto using stereotactic guidance to deliver high doses of radiation to the prostate over a 1 to 2 week period of time suggest that outcomes may be equal or superior to standard approaches. These data, combined with markedly improved convenience for patients, make radiosurgery (SBRT) for early-stage prostate cancer an enticing option. The goal of this study is to offer a radiosurgical option to patients within the Sharp system under the umbrella of an IRB-approved study.

Conditions

• Prostatic Neoplasm

Interventions

Type	Name	Description
RADIATION	Radiation Therapy	Stereotactic Body Radiation Therapy

Timeline

• Start date: 2011-01-01
• Primary completion: 2019-04-05
• Completion: 2019-04-05
• First posted: 2012-02-29
• Last updated: 2025-01-16
• Results posted: 2025-01-16

Locations

1 site across 1 country: United States